Repligen Corp.

RGEN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $48.9M $-25.5M $35.6M $186.0M $128.3M $59.9M $21.4M $16.6M
Depreciation & Amortization $78.7M $69.7M $68.6M $51.0M $38.4M $27.1M $20.9M $15.8M
Depreciation $39.7M $35.0M $37.0M $23.9M $16.4M $10.9M $7.3M $5.2M
Amortization $39.1M $34.7M $31.6M $27.1M $22.1M $16.1M $13.6M $10.6M
Stock-Based Compensation $32.6M $48.1M $25.6M $27.3M $27.5M $17.0M $12.8M $10.2M
Net Cash from Operating Activities $117.4M $175.4M $113.9M $172.1M $119.0M $62.6M $67.2M $32.8M
Investing Activities
Capital Expenditures $23.5M $25.7M $36.2M $84.8M $67.1M $22.5M $18.5M $10.6M
Business Acquisitions $70.3M $54.8M $186.6M $0 $149.9M $175.0M $182.2M
Net Cash from Investing Activities $-298.5M $-86.4M $-123.3M $-233.2M $-221.2M $-201.4M $-205.3M $-14.0M
Financing Activities
Dividends Paid
Stock Repurchases $0 $0 $14.4M $0 $0
Net Cash from Financing Activities $-15.2M $-82.9M $249.0M $-13.3M $961.0K $305.9M $484.9M $3.4M
Net Change in Cash $-191.3M $6.0M $227.9M $-80.4M $-113.5M $179.9M $343.6M $20.1M
Free Cash Flow $93.9M $149.7M $77.7M $87.2M $51.9M $40.2M $48.7M $22.1M
← Newer Page 1 of 2 Older →